SCHIZOPHRENIA

Recruiting for Phase 2 Study

We are currently recruiting for our Phase 2 study to evaluate the efficacy, safety, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.

Clinical Trials are Open in the United States and Australia:

NCT06442462
Status: Recruiting

Locations
Garden Grove, California, United States, 92845

Contact: CNS Outreach and Recruitment
844-424-9494
cns.info@cenexel.com


MAPrc, Melbourne VIC, Australia

Contact: Emorfia Gavrilidis at MAPrc 
emmy.gavrilidis@monash.edu

For additional information, visit ClinicalTrials.gov